Dr. Reddy's registers PD-1 inhibitor in South Africa for recurrent or metastatic nasopharyngeal carcinoma
RDY•South Africa registers Dr. Reddy's PD-1 inhibitor
South African regulators registered a PD-1 inhibitor from Dr. Reddy’s Laboratories for recurrent or metastatic nasopharyngeal carcinoma.
The authorization expands local access to immunotherapy for a rare head and neck cancer with limited treatment options.
GLOBOCAN 2024 put five-year prevalence in South Africa at 0.66 cases per 100,000 people.
